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Introduction
Prion diseases are characterized by deposition of PrPSc, a
misfolded and aggregated isoform of the host-encoded cellular
prion protein (PrPC), within the central nervous system (CNS)
and other organs. Here we review the current knowledge on five
issues relevant to prion diseases: (1) how do prions enter the body,
(2) how do prions reach the central nervous system, (3) how do
prions damage the CNS, (4) do mammals have an antiprion
defense system, and (5) how can the prion problem be resolved
for good.
How Do Prions Enter the Body?
Most cases of human prion disease occur for unknown reasons,
and.20 mutations in the prion gene (PRNP) may lead to inherited
prion disease. In other instances, prion diseases are contracted by
exposure to prion infectivity. Save for direct brain exposure by
neurosurgery, prions typically enter the body through extraneural
pathways. This raises the intriguing question of how a mere
protein aggregate can trespass mucosal barriers, circumvent innate
and adaptive immunity, and travel across the blood–brain barrier
to eventually provoke brain disease.
Oral Uptake
There is no doubt that prion infections can be efficaciously
transmitted under both natural and human-made conditions.
While some aspects of the natural transmission of scrapie and
chronic wasting disease (CWD) remain unexplained, oral
transmission of prions has caused large epidemics and epizootics.
Kuru, a human prion disease transmitted through ritual
cannibalism, has afflicted the Fore people of Northern Papua
New Guinea at extraordinarily high rates. Bovine spongiform
encephalopathy (BSE), which has killed more than 280,000 cattle
worldwide, is a prion disease caused by the feeding of recycled
prion-infected foodstuff to cattle [1]. In turn, variant Creutzfeldt-
Jacob Disease (vCJD), which has claimed over 200 victims,
appears to be caused by consumption of BSE-contaminated beef
products [2].
Parenteral Uptake
Prions can also enter the body via parenteral uptake. Most
worryingly, vCJD has been transmitted from subclinically vCJD-
infected donors to recipients of transfused non-leukocyte-reduced
red cells and of purified factor VIII preparations [3]. By far the
largest incident involving iatrogenic prion transmission involved
human pituitary hormones. Before the advent of recombinant
DNA technology, growth hormone (used to treat dwarfism) and
fertility hormones were recovered from human cadaveric pituitary
glands. The prevalence of subclinically CJD-affected donors,
probably coupled with brain-tissue contamination of pituitary
extracts, led to over 160 prion deaths in mostly young recipients.
Experimentally, the parenteral route of prion transmission is very
effective and, e.g., intraperitoneal (i.p) inoculation of prions to
laboratory animals is a widely used route for studies of peripheral
prion replication and neuroinvasion.
Intracerebral Administration
The most efficient way of prion transmission is intracerebral
(i.c) administration. This is not unexpected, since the brain is the
main target of prion toxicity and administration to the brain
bypasses all natural barriers to prion neuroinvasion, such as the
innate and adaptive immune system, as well as the blood–brain
barrier.
Several iatrogenic CJD (iCJD) transmissions occurred via
neurosurgery and dura mater grafts. These cases were particularly
tragic for all those involved because they were inadvertently
caused by medical personnel and represented an untoward effect
of the intent to treat other ailments. Some of the first well-
documented instances of intracerebral prion transmission to
humans occurred in Zu¨rich in the 1970s [4]. Electrodes were
used for stereotactic electroencephalographic (EEG) recordings in
a CJD patient, and reused after sterilization with ethanol and
formaldehyde vapors—a procedure that reliably inactivates viruses
and bacteria, but is ineffective against prions. This resulted in fatal
prion transmission to two young patients. The infectivity on these
electrodes was later confirmed by transmission of CJD to a
chimpanzee.
Aerosols
Prion transmission is usually not considered to be airborne
like influenza or chicken pox. But we and others recently have
found that prions can also be efficiently transmitted to mice
through aerosols [5,6]. Although aerosol-transmitted prions
have never been found under natural conditions, this finding
highlights the necessity of revising the current prion-related
biosafety guidelines and health standards in diagnostic and
scientific laboratories being potentially confronted with prion-
infected materials.
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How Do Prions Reach the Central Nervous
System?
Role of B Cells
Prior to invading the CNS, prions frequently colonize in
lymphoid organs (Fig. 1), where they colocalize with follicular
dendritic cells (FDCs). The maintenance of FDCs depend on B
cell-derived lymphotoxins (LTs) and tumor necrosis factor (TNF);
accordingly, B cell–deficient mice (mMT, Rag12/2, Rag22/2)
that lack mature FDCs are resistant to extraneural prion challenge
[7]. However, the expression of PrPC in B cells is dispensable, and
transgenic expression of PrPC restricted to B cells cannot restore
prion replication or neuroinvasion in Prnp knockout mice.
Therefore, B cells may function in an indirect way in prion
diseases. It is reasonable to envision that B cells secrete factors
(LTs, TNFs, etc.) that facilitate the maturation of cells like FDCs to
replicate/accumulate prions.
Role of Follicular Dendritic Cells
The immune system plays an important role in prion
pathogenesis, but the exact nature of the cells replicating prions
extraneurally is still unclear. FDCs are usually considered to be the
main sites accumulating prions. Prion replication in lymphoid
organs depends on PrPC-expressing FDCs, at least for the ME7
prion strain [8]. However, TNF receptor 1 knockout (TNFR12/2)
mice that lack mature FDCs are fully susceptible to peripheral
prion infection and develop high prion titers in lymph nodes [9].
Furthermore, inflammatory granulomas that lack FDCs can also
replicate prions in a lymphotoxin-dependent manner [10]. These
results indicate cells other than FDCs are able to replicate prions
extraneurally.
Role of Autonomic Nerves
After replication and accumulation in lymphoid organs, prions
invade the nervous system through sympathetic and parasympa-
thetic nerves [11,12]. The spread pathways of prions were
determined by identifying the location and temporal sequence of
pathological accumulation of PrP after oral challenge [11]. Upon
i.p inoculation, permanent or transient sympathectomy chemically
or immunologically delays or even prevents scrapie, whereas
sympathetic hyperinnervation accelerates prion pathogenesis [12].
Hence innervation of lymphoid organs is rate-limiting for prion
neuroinvasion. Furthermore, neuroinvasion velocity depends on
the distance between FDCs and splenic nerves, suggesting that the
neuroimmune transition of prions occurs between FDCs and
sympathetic nerves.
How Do Prions Damage the CNS?
The details of how prions induce toxicity are still unclear.
Canonical caspase-mediated apoptosis is unlikely to be important,
yet other pathways of cell death have remained largely
unexplored. However, all attempts at a rational therapy necessitate
a thorough understanding of how prions bring about the
horrendous damage seen in spongiform encephalopathies.
PrPC: An Amyloid Receptor?
PrPC expression is indispensable for prion-induced neurotoxic-
ity [13], implying PrPC could be a receptor for prions to trigger
detrimental signaling. The scenario could be broader. Strittmatter
reported that PrPC transduces the synaptic toxicity of amyloid-b
(Ab) oligomers in vitro [14]and in Ab transgenic mice (APPswe/
PSen1DE9) [15]. Moreover, different anti-PrP antibodies or their
antigen-binding fragments that disrupt the PrP–Ab interaction
were able to block the Ab-mediated disruption of synaptic
plasticity. These findings were deemed exciting because they
suggest the involvement of PrPC in Alzheimer’s disease (AD)
pathogenesis. However, others found that the absence of PrPC did
not prevent deficits in hippocampal-dependent behavioral tests
upon intracerebral Ab injection [16]. Even more troubling was the
report by Malinow [17] that Strittmatter’s results could not be
reproduced in a virtually identical paradigm. It has been suggested
by Gerald Zamponi that variations in copper availability may
contribute to these discrepancies.
We also crossed mice lacking or overexpressing PrPC to the
APPPS1 (APPKM670/671NL/PS1L166P) transgenic mice, yet did not
see any effect of PrPC on the impairment of hippocampal synaptic
Figure 1. The cascade of prion entry, peripheral replication, neuroinvasion, and neurodegeneration. After peripheral exposure, prions
colonize and replicate in secondary lymphoid organs (SLOs) like spleen, Payer’s patches, lymph nodes, and tonsils. FDCs are the main sites
accumulating prions in SLOs. B cell-derived LTs and TNF facilitate prion accumulation by supporting development and maintenance of FDCs.
Dedifferentiation of FDCs by LTbR-Ig delays neuroinvasion, whereas repetitive immunization accelerates prion pathogenesis. Prions reach the central
nervous system (CNS) through autonomic nerves, directly after intracerebral inoculation, or via aerosols through immune-independent pathways. In
the brain, prions replicate but are also cleared by microglia after opsonisation by astrocyte-borne Mfge8. Prion deposition comes about when PrPSc
production exceeds PrPSc clearance.
doi:10.1371/journal.ppat.1002651.g001
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plasticity [18]. To make things even more confusing, another AD
mouse model disproved any impact of PrPC on Ab-mediated
neurotoxicity, whereas other studies appear to indirectly support
the Strittmatter findings. Consequently, the question of whether
PrPC is a transducer of amyloid toxicity remains essentially
unanswered. The discrepancies listed above do not necessarily
result from any blatant flaws in the studies performed thus far, but
rather indicate that some parameters affecting amyloid toxicity
may still be unknown and, consequently, beyond the reach of
rigorous testing.
Shmerling’s Disease and Baumann’s Disease
Interstitially deleted PrPC variants (D32–134; D94–134) elicit
spontaneous neurodegeneration (Shmerling’s and Baumann’s
disease), which is rescued by co-expression of full-length PrPC
[19,20]. This suggests that truncated PrPC competes with PrPC-
like molecules through a shared receptor [20,21]. Transgenic mice
expressing deletion extended to the very end of N-terminus of
PrPC (D23–134) are healthy, suggesting that residues 23–31 are
involved in Shmerling’s and Baumann’s disease [22].
Perhaps the key to understanding toxicity is the relationship
between the N terminal tail and the plasma membrane. The
amino terminus of full-length PrPC is kept away from the
membrane by the bulky globular domain. Perhaps the toxic
mutants engage in deleterious interactions between the amino
terminus and the membrane, possibly resulting in the formation of
toxic pores [23].
Lessons from Human Mutations
Transgenic mice expressing PrPC with 14 octapeptide repeats
insertion (PG14) in both Prnp+/+ and Prnp2/2 background
displayed neurodegeneration similar to the disease of humans
affected by a similar mutation [24]. In contrast to the syndromes
described above, this pathology was not rescued by coexpression of
PrPC, suggesting that the supernumerary octapeptides repeat
expansion of PG14 PrP might induce neurodegeneration through
another pathway distinct from Shmerling’s and Baumann’s
disease. Accordingly, Shmerling’s and Baumann’s disease may
arise through an allosteric mechanism, with the globular domain
exerting its influence on the geometry of the amino terminal tail,
whereas PG14 disease may be directly elicited by octapeptide
repeats.
Do Mammals Have an Antiprion Defense System?
Evidence for Rapid Prion Clearance In Vivo
Progressive accumulation of PrPSc can only occur if conversion
of PrPC into PrPSc is faster than PrPSc clearance. Therefore,
studying the clearance of prions is arguably as important as
studying their generation. Prnp2/2 mice develop more or less
normally yet cannot replicate prions, making them a perfect model
to study the half-life of the prion. Upon inoculation, residual
infectivity all but disappears within 4 days, indicating that prions—
commonly regarded as the sturdiest pathogens on earth—can be
cleared in vivo with astonishing efficiency and speed. The
identification of molecules and cells involved in prion clearance
will be of great importance for therapeutics of prion diseases.
Prion Clearance: Extracellular Proteolysis or
Phagocytosis?
Neprilysin is a metalloprotease known to degrade extracellular
amyloid such as Ab. However, mice lacking or overexpressing
neprilysin experience no changes in prion pathogenesis. There-
fore, prion clearance may be effected by extracellular proteases
other than neprilysin, or by different mechanisms altogether [25].
In organotypic cerebellar slices, the pharmacogenetic ablation of
microglia led to a 15-fold increase in prion titers [26], suggesting
that microglia are the primary effector of prion clearance.
The Role of Mfge8
Microglia disposes of CNS debris (possibly including supernu-
merary synapses) by phagocytosis. But how can microglia identify
prions as edible material? Milk fat globule epidermal growth factor
8 (Mfge8), a bridging molecule mediating phagocytosis of
apoptotic cells, may represent a crucial link. Mfge82/2 mice
showed accelerated prion pathogenesis, accompanied with re-
duced clearance of cerebral apoptotic bodies and increased PrPSc
accumulation and prion titers [27], suggesting Mfge8-mediated
prion clearance in prion-infected mouse brain. More interestingly,
these were observed in C57BL/66129Sv but not in C57BL/6
genetic background. Therefore, besides Mfge8, other molecules
involved in phagocytosis of apoptotic cells could have the potential
to clear prions in vivo, it is worth putting more efforts on them.
How Can the Prion Problem Be Resolved for
Good?
PrPC-Deficient Farm Animals: Technology and Hurdles
The absence of PrPC is the only absolute guarantee that an
organism will resist prion infections. Therefore it is of great
practical interests to generate PrPC-deficient farm animals.
Although it is unknown how tasty PrPC-deficient steaks might
be, such farm animals would provide perfectly prion-free resources
for all kinds of biologicals—including cytokines, growth factors,
and therapeutic antibodies. Because embryonic stem cells are not
available for gene targeting in other species, knockout farm
animals were obtained by gene targeting of somatic cells followed
by nuclear transfer. The first attempt to knock out PRNP in sheep
was reported in 2001, but the cloned PRNP+/2 sheep perished
soon after birth—probably because of defective cloning proce-
dures. In 2007, viable PRNP knockout cattle were obtained by
sequential gene targeting in somatic cells and nuclear transfer.
Targeted disruption of PRNP in goats, which frequently suffer
from the prototypic prion disease, scrapie, was accomplished
through a similar strategy [28,29].
Usefulness of PrPC-Deficient in Production of Biologicals
Biologicals are accounting for an ever increasing fraction of all
therapeutics—yet all eukaryotically produced biologicals bear a
certain risk of prion contamination, even when generated in cell
lines. The transmission of vCJD through blood and even purified
blood products has dramatically highlighted the seriousness of this
threat. Therefore, PrPC-deficient farm animals (cattle and goats)
are well positioned for the production of prion-free therapeutics
and will therefore make an important contribution towards
eliminating the risk of prions contamination in biologicals.
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